Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon α-2b plus Ribavirin for Naïve Patients with Chronic Hepatitis C?
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Objective: To compare the cost effectiveness of different therapeutic strategies using the combination of interferon and ribavirin in the treatment of patients with chronic hepatitis C.
Design and setting: This was a cost-effectiveness analysis from the perspective of the Spanish healthcare system.
Methods: Six different therapeutic strategies were compared using a decisiontree analysis and a Markov model. These strategies, using combination therapy for 24 or 48 weeks depending on viral genotype and hepatitis C virus (HCV) RNA, were compared on the basis of incremental cost per additional life year saved (LYS) and additional quality-adjusted life year (QALY) saved. Clinical data were derived from major clinical trials and costs from the Spanish healthcare system.
Results: For a base-case patient with chronic hepatitis C, the most effective strategy was combination therapy for 24 weeks for genotype non-1 and for 48 weeks for genotype 1 patients who cleared HCV RNA before week 24. Using this strategy, life expectancy increased by 0.07 to 0.38 years vs other strategies and QALY increased 0.15 to 0.84 vs other strategies. The incremental cost per LYS ranged from cost saving to euros (EUR)1363, and per QALY from cost saving to EUR610 vs other strategies (2000 values, converted to EUR at the official rate of 1EUR = 166.386 pesetas). The cost per LYS and QALY compared with no therapy was EUR2368 and EUR1060, respectively. This strategy permits the treatment of more patients with the same budget than those strategies based only on HCV genotyping or HCV RNA testing.
Conclusion: Defining the duration of combination therapy for patients with chronic hepatitis C by baseline genotyping and HCV RNA testing at week 24 is the best strategy for standard clinical practice.
- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32 CrossRef
- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92 CrossRef
- EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956–61
- Younossi ZM, Singer ME, McHutchison JG, et al. Cost-effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–24 CrossRef
- Poynard T, McHutchinson J, Goodman Z, et al. Is an ‘a la carte’ combination of interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 211–8 CrossRef
- Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–74
- Bennett WG, Inoue Y, Beck R, et al. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65
- Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000; 33: 651–8 CrossRef
- Wong JB, Poynard Y, Ling M-H, et al. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000; 95: 1524–30
- Buti M, Casado MA, Fosbrook L, et al. Coste-efectividad de la hepatitis crónica C con interferon alfa. Gastroenterol Hepatol 1998; 21: 161–8
- Data from SOIKOS. Base de Datos de Costes Sanitarios, 1999
- Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996; 9: 113–20 CrossRef
- Camma C, Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531–7 CrossRef
- Lau DTY, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-⇌ therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–7 CrossRef
- Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–81
- Reichard O, Glaumann H, Frydén A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783–7 CrossRef
- Freedberg KA, Losina E, Weinstein M, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824–31 CrossRef
- Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000; 90: 1562–9 CrossRef
- Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403 CrossRef
- Hetachote EJ, Siffman M, Cooksley E, et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–80 CrossRef
- Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon α-2b plus Ribavirin for Naïve Patients with Chronic Hepatitis C?
Clinical Drug Investigation
Volume 22, Issue 1 , pp 31-39
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors